Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice

Ulcerative colitis is a chronic recurrent disease characterized by acute inflammation of the colonic mucosa. In Japan, a dietary supplementation product enriched with glutamine, dietary fiber, and oligosaccharide (GFO) is widely applied for enteral nutrition support. These three components have been...

Full description

Saved in:
Bibliographic Details
Published inNutrition (Burbank, Los Angeles County, Calif.) Vol. 29; no. 3; pp. 549 - 555
Main Authors Joo, Erina, Yamane, Shunsuke, Hamasaki, Akihiro, Harada, Norio, Matsunaga, Tetsuro, Muraoka, Atsushi, Suzuki, Kazuyo, Nasteska, Daniela, Fukushima, Toru, Hayashi, Tatsuya, Tsuji, Hidemi, Shide, Kenichiro, Tsuda, Kinsuke, Inagaki, Nobuya
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.03.2013
Elsevier
Elsevier Limited
Subjects
GFO
GFO
Online AccessGet full text
ISSN0899-9007
1873-1244
1873-1244
DOI10.1016/j.nut.2012.09.007

Cover

More Information
Summary:Ulcerative colitis is a chronic recurrent disease characterized by acute inflammation of the colonic mucosa. In Japan, a dietary supplementation product enriched with glutamine, dietary fiber, and oligosaccharide (GFO) is widely applied for enteral nutrition support. These three components have been suggested to improve intestinal health. In this study, we investigated whether GFO has suppressive effects on mucosal damage in ulcerative colitis in an experimental mouse model. C57BL/6 mice received 2.5% dextran sulfate sodium in drinking water for 5 d to induce colitis. Then, they were given 0.25 mL of GFO or a 20% glucose solution twice daily for 10 d. Another set of mice receiving unaltered drinking water was used as the normal control group. The body weight loss and disease activity index were significantly lower in the GFO-treated mice compared with the glucose-treated mice (P < 0.05). The decrease in colon length induced by dextran sulfate sodium was significantly alleviated in GFO-treated mice compared with glucose-treated mice (P < 0.01). In addition, the histologic findings showed that intestinal inflammation was significantly attenuated in mice treated with GFO. Furthermore, treatment with GFO significantly inhibited the dextran sulfate sodium–induced increase in the mRNA expression of interleukin-1β. These results suggest that GFO has potential therapeutic value as an adjunct therapy for ulcerative colitis.
Bibliography:http://dx.doi.org/10.1016/j.nut.2012.09.007
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
content type line 14
ObjectType-Feature-3
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0899-9007
1873-1244
1873-1244
DOI:10.1016/j.nut.2012.09.007